Immune Checkpoint Inhibitors-Associated Generalized Lipodystrophy: Reconstructive Challenges of an Emerging and Distinct Form of Lipodystrophy.
Journal
The Journal of craniofacial surgery
ISSN: 1536-3732
Titre abrégé: J Craniofac Surg
Pays: United States
ID NLM: 9010410
Informations de publication
Date de publication:
13 Jun 2024
13 Jun 2024
Historique:
received:
18
04
2024
accepted:
21
05
2024
medline:
13
6
2024
pubmed:
13
6
2024
entrez:
13
6
2024
Statut:
aheadofprint
Résumé
Total and permanent loss of facial and nonfacial fat is a rare side effect of immune checkpoint inhibitors (ICIs). Consequently, effective treatment modalities for patients remain undefined. Here, we discuss the surgical treatment of a patient with both ICI-related acquired generalized lipodystrophy (AGL). We additionally performed a comprehensive literature review (Cochrane, Embase, and MEDLINE) to summarize what is known about ICI-related lipodystrophy and available treatments for this rare complication. A 66-year-old female diagnosed with metastatic lung adenocarcinoma started ICI (pembrolizumab) treatment. She developed generalized lipodystrophy 13 months after her first cycle. Her primary concern was the loss of facial fat volume, which significantly aged her appearance. The patient underwent a 2-staged restoration of her facial fat compartments using dermal grafts from the lower abdomen and medial thighs. The patient recovered uneventfully and was satisfied with the aesthetic improvement at 18 months of follow-up. The authors identified 8 case reports with patients with ICI-AGL. The mean age was 53.63 years, and the mean BMI was 36.72 kg/m2. The average onset of symptoms was 7.44 months after ICI initiation. None of the studies described any sort of surgical or nonsurgical options to restore the volume of the facial fat compartments. The management of combined facial and nonfacial lipodystrophy remains challenging due to the lack of suitable autologous fat donor sites. In this report, the authors demonstrate that staged volume restoration can be achieved using autologous dermal grafts from the thigh, making it a viable reconstructive option in this subset of patients.
Identifiants
pubmed: 38869298
doi: 10.1097/SCS.0000000000010409
pii: 00001665-990000000-01716
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 by Mutaz B. Habal, MD.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
Darvin P, Toor SM, Sasidharan Nair V, et al. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med 2018;50:1–11
Gnanendran SS, Miller JA, Archer CA, et al. Acquired lipodystrophy associated with immune checkpoint inhibitors. Melanoma Res 2020;30:599–602
Stelmachowska-Banaś M, Czajka-Oraniec I. Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review. Endocr Connect 2020;9:r207–r228
Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 2019;16:563–580
Drexler K, Zenderowski V, Berneburg M, et al. Facial lipodystrophy after immunotherapy with Nivolumab. J Dtsch Dermatol Ges 2021;19:1513–1515
Falcao CK, Cabral MCS, Mota JM, et al. Acquired lipodystrophy associated with nivolumab in a patient with advanced renal cell carcinoma. J Clin Endocrinol Metab 2019;104:3245–3248
Haddad N, Vidal‐Trecan T, Baroudjian B, et al. Acquired generalized lipodystrophy under immune checkpoint inhibition. Br J Dermatol 2020;182:477–480
Jehl A, Cugnet-Anceau C, Vigouroux C, et al. Acquired generalized lipodystrophy: a new cause of anti-PD-1 immune-related diabetes. Diabetes Care 2019;42:2008–2010
Bedrose S, Turin CG, Lavis VR, et al. A case of acquired generalized lipodystrophy associated with pembrolizumab in a patient with metastatic malignant melanoma. AACE Clin Case Rep 2020;6:e40–e45
Eigentler T, Lomberg D, Machann J, et al. Lipodystrophic nonalcoholic fatty liver disease induced by immune checkpoint blockade. Ann Intern Med 2020;172:836–837
Unal MC, Semiz GG, Ozdoğan O, et al. Nivolumab associated endocrine abnormalities: challenging cases from a reference clinic. Acta Endocrinol (Buchar) 2022;18:516–522
Chiquette E, Oral EA, Garg A, et al. Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges. Diabetes Metab Syndr Obes 2017;10:375–383
Dhanasekaran M, Sandooja R, Higgins A, et al. Marked hypoleptinemia precedes overt fat loss in immune checkpoint inhibitor-induced acquired generalized lipodystrophy. J Clin Lipidol 2022;16(3 suppl):e42
Rohrich RJ, Pessa JE. The fat compartments of the face: anatomy and clinical implications for cosmetic surgery. Plast Reconstr Surg 2007;119:2219–2227
Rohrich RJ, Avashia YJ, Savetsky IL. Prediction of facial aging using the facial fat compartments. Plast Reconstr Surg 2021;147(1s-2):38s–42s
Kreutz-Rodrigues L, Shapiro D, Mardini S, et al. Landmarks in facial rejuvenation surgery: the top 50 most cited articles. Aesthet Surg J 2020;40:np1–np7
James J, Carruthers A, Carruthers J. HIV-associated facial lipoatrophy. Dermatol Surg 2002;28:979–986
Teplica D, Bohorquez M, Podbielski FJ. Morcellized omental transfer for severe HIV facial wasting. Plast Reconstr Surg Glob Open 2013;1:e73
Martin A, Smith DE, Carr A, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. Aids 2004;18:1029–1036
Vallejo A, Garcia-Ruano AA, Pinilla C, et al. Comparing efficacy and costs of four facial fillers in human immunodeficiency virus-associated lipodystrophy: a clinical trial. Plast Reconstr Surg 2018;141:613–623
Guzman N, Vijayan V. HIV-associated Lipodystrophy. InStatPearls [Internet] 2022 Nov 7. StatPearls Publishing
Guaraldi G, De Fazio D, Orlando G, et al. Facial lipohypertrophy in HIV-infected subjects who underwent autologous fat tissue transplantation. Clin Infect Dis 2005;40:e13–e15
Nelson L, Stewart KJ. Plastic surgical options for HIV-associated lipodystrophy. J Plast Reconstr Aesthet Surg 2008;61:359–365
Carey D, Liew S, Emery S. Restorative interventions for HIV facial lipoatrophy. AIDS Rev 2008;10:116–124
Mori A, Lo Russo G, Agostini T, et al. Treatment of human immunodeficiency virus-associated facial lipoatrophy with lipofilling and submalar silicone implants. J Plast Reconstr Aesthet Surg 2006;59:1209–1216
Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. Aids 2003;17(suppl 1):S141–S148
Tartaro G, Pinto L, Lo Giudice G, et al. Polyacrylamide injection vs. polylactic acid in HIV related lipodystrophy: a RCT systematic review. Appl Sci 2021;11:8195
Strauch B, Baum T, Robbins N. Treatment of human immunodeficiency virus-associated lipodystrophy with dermafat graft transfer to the malar area. Plast Reconstr Surg 2004;113:363–370; discussion 371–372